Literature DB >> 19427222

Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.

Dennis A Brown1, Manoj Mishra, Suhong Zhang, Swati Biswas, Ingrid Parrington, Tamara Antonio, Maarten E A Reith, Aloke K Dutta.   

Abstract

Here we report on the design and synthesis of several heterocyclic analogues belonging to the 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol series of molecules. Compounds were subjected to [(3)H]spiperone binding assays, carried out with HEK-293 cells expressing either D2 or D3 dopamine receptors, in order to evaluate their inhibition constant (K(i)) at these receptors. Results indicate that N-substitution on the piperazine ring can accommodate various substituted indole rings. The results also show that in order to maintain high affinity and selectivity for the D3 receptor the heterocyclic ring does not need to be connected directly to the piperazine ring as the majority of compounds included here are linked either via an amide or a methylene linker to the heterocyclic moiety. The enantiomers of the most potent racemic compound 10e exhibited differential activity with (-)-10e (K(i); D2=47.5 nM, D3=0.57 nM) displaying higher affinity at both D2 and D3 receptors compared to its enantiomer (+)-10e (K(i); D2=113 nM, D3=3.73 nM). Additionally, compound (-)-10e was more potent and selective for the D3 receptor compared to either 7-OH-DPAT or 5-OH-DPAT. Among the bioisosteric derivatives, the indazole derivative 10g and benzo[b]thiophene derivative 10i exhibited the highest affinity for D2 and D3 receptors. In the functional GTPgammaS binding study, one of the lead molecules, (-)-15, exhibited potent agonist activity at both D2 and D3 receptors with preferential affinity at D3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427222      PMCID: PMC2701157          DOI: 10.1016/j.bmc.2009.04.031

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  27 in total

Review 1.  Dopamine receptors--physiological understanding to therapeutic intervention potential.

Authors:  G Emilien; J M Maloteaux; M Geurts; K Hoogenberg; S Cragg
Journal:  Pharmacol Ther       Date:  1999-11       Impact factor: 12.310

2.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach.

Authors:  Judith Varady; Xihan Wu; Xueliang Fang; Ji Min; Zengjian Hu; Beth Levant; Shaomeng Wang
Journal:  J Med Chem       Date:  2003-10-09       Impact factor: 7.446

Review 3.  Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders.

Authors:  Robert R Luedtkea; Robert H Mach
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

4.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 5.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

6.  Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.

Authors:  Swati Biswas; Stuart Hazeldine; Balaram Ghosh; Ingrid Parrington; Eldo Kuzhikandathil; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2008-04-12       Impact factor: 7.446

7.  A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: binding activity at D2 and D3 receptors.

Authors:  Aloke K Dutta; Xiang-Shu Fei; Maarten E A Reith
Journal:  Bioorg Med Chem Lett       Date:  2002-02-25       Impact factor: 2.823

8.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

Review 9.  Dopamine receptor agonists in the therapy of Parkinson's disease.

Authors:  P Foley; M Gerlach; K L Double; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2003-12-29       Impact factor: 3.575

10.  Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.

Authors:  Aloke K Dutta; Sylesh K Venkataraman; Xiang-Shu Fei; Rohit Kolhatkar; Shijun Zhang; Maarten E A Reith
Journal:  Bioorg Med Chem       Date:  2004-08-15       Impact factor: 3.641

View more
  6 in total

1.  Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.

Authors:  Mark Johnson; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2012-06-13       Impact factor: 7.446

2.  Efficient Pd-catalyzed amination reactions for heterocycle functionalization.

Authors:  Jaclyn L Henderson; Stephen L Buchwald
Journal:  Org Lett       Date:  2010-10-15       Impact factor: 6.005

Review 3.  Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors.

Authors:  Jaromir Myslivecek
Journal:  Life (Basel)       Date:  2022-04-19

4.  Understanding the Structural Requirements of Hybrid (S)-6-((2-(4-Phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol and its Analogs as D2/D3 Receptor Ligands: A Three-Dimensional Quantitative Structure-Activity Relationship (3D QSAR) Investigation.

Authors:  Gyan Modi; Horrick Sharma; Prashant S Kharkar; Aloke K Dutta
Journal:  Medchemcomm       Date:  2014-09-01       Impact factor: 3.597

5.  Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.

Authors:  Banibrata Das; Seenuvasan Vedachalam; Dan Luo; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2015-11-30       Impact factor: 7.446

6.  Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.

Authors:  Balaram Ghosh; Tamara Antonio; Juan Zhen; Prashant Kharkar; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.